# Breast Cancer Research Program

> **NIH NIH P30** · UNIV OF NORTH CAROLINA CHAPEL HILL · 2022 · $46,834

## Abstract

ABSTRACT: BREAST CANCER PROGRAM
The Breast Cancer Program (BC) was an outgrowth of the basic, translational, population and clinical research
of the LCCC Breast Cancer SPORE, which has been continuously funded since 1992. LCCC investment in
faculty and infrastructure supports one of the country’s premier clinical and research breast programs,
performing important interdisciplinary research in the past decade with members rising to national leadership
positions. This knitting together of clinical, basic, and epidemiologic research is the hallmark of the Breast
Program, and is reflected in the investment in faculty and resources fostered by including, in the last 5 years,
over $10M in genomics/sequencing resources used for institutional as well as large multicenter trials. This
commitment is reflected in patient-facing institutional trials examining clinical implications of breast cancer
subtypes as well as LCCC leadership of collaborative tissue-based studies through the Translational Breast
Cancer Research Consortium (TBCRC) and AURORA-US Project (https://auroraus.org), a multicenter,
multiplatform analysis of DNA, RNA, and other alterations in metastases compared with matched primary
tumors. The longitudinal and exceptional investment in the Carolina Breast Cancer Studies (CBCS) represents
the largest and most heavily annotated population-based study ever performed addressing racial disparities in
breast cancer, behavior and outcome. CBCS has received an additional $5M investment in this cycle and is
providing the community with an increased understanding of the full range of breast cancer research from
genomics /genetics to health services. Program strategic goals include: 1) genomic and genetic analyses of
metastatic and primary breast cancers, 2) bench-to-bedside approaches using murine models, 3) translational
discovery and strategies based on human tissue-based correlative science, 4) clinical trials and population-
based studies leveraging and applying UNC science and community input to address the root causes of
disparities. BC members include clinicians, basic researchers, statisticians, bioinformaticians, epidemiologists,
and health services scientists. BC has long-term interest in North Carolina’s minority disparities, following the
program’s seminal discoveries of the high incidence of triple negative breast cancer (TNBC) in younger African
Americans, the subsequent molecular analysis showing the disparity is even more striking, and the surprising
finding that the largest racial disparity in survival is in women with hormone receptor-positive disease, for
whom access to care and adherence to treatment are key. The BC Program consists of 21 members who are
associated with 10 basic science and 5 clinical departments at UNC-Chapel Hill and affiliated institutions.
During the last funding period, program members published 494 cancer-related articles, of which 56% were
inter-programmatic and 15% were intra-programmatic (57% collaborative)....

## Key facts

- **NIH application ID:** 10320879
- **Project number:** 5P30CA016086-46
- **Recipient organization:** UNIV OF NORTH CAROLINA CHAPEL HILL
- **Principal Investigator:** LISA A CAREY
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $46,834
- **Award type:** 5
- **Project period:** 1997-06-01 → 2025-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10320879

## Citation

> US National Institutes of Health, RePORTER application 10320879, Breast Cancer Research Program (5P30CA016086-46). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10320879. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*